Get started

Pfizerinc

Pfizer Stock: More Than Just COVID-19 VaccinesYou may be familiar with the negative sentiment surrounding Pfizer, with many citing the company's heavy reliance on its COVID-19 vaccine Comirnaty and antiviral therapy Paxlovid as a cause for concern. In addition to this, several of Pfizer's top-selling drugs will face patent expirations in the near future, leading many to believe that the company's stock will suffer. While there are certainly challenges facing Pfizer, the conclusion that its stock will suffer is flawed. Despite the company's current predicament, there is a lot to be excited about. Let's explore why Pfizer's stock is becoming increasingly attractive. Over the past five weeks, Pfizer has received a string of positive news. The U.S. Food and Drug Administration (FDA) approved Cibinqo for the treatment of adolescents with atopic dermatitis, marking a significant milestone for the company's growth strategy. Additionally, a late-stage study evaluating the combination of Talzenna and Xtandi to treat metastatic castration-resistant prostate cancer produced positive results, reducing the risk of disease progression or death by 37%. Furthermore, Pfizer announced that regulatory applications for elranatamab had been accepted by the FDA and the European Medicines Agency for the treatment of multiple myeloma. The company expects FDA approval to be granted later this year. In addition, an FDA advisory committee voted to approve Pfizer's respiratory syncytial virus (RSV) vaccine for older adults, which could open up a major market opportunity for the company. On March 10, the FDA approved Zavzpret for the treatment of migraine. Pfizer acquired the drug as part of its purchase of Biohaven in 2022. The company also announced plans to acquire Seagen for $43 billion, which caused Pfizer's stock to rise significantly. The acquisition will provide Pfizer with four approved cancer drugs and promising antibody-drug conjugates (ADCs) that could generate $10 billion in risk-adjusted revenue by 2030. Despite all of these positive developments, Pfizer's stock remains undervalued by investors. Its price is still nearly 35% below its late 2021 high, trading at just 12 times expected earnings. However, the company's dividend has risen to 4.1%, its highest level since mid-2021. Investors seem to be fixated on the difficulties associated with COVID-19 and its treatment, but Pfizer predicts that even on this front, there is good news to come. The company expects demand for Comirnaty to rise to 98 million doses by 2026 due to the launch of the combination flu vaccine COVID. Additionally, demand for Paxlovid is predicted to grow steadily over the next few years, with the possibility of promoting antiviral therapy in China. In conclusion, while there are certainly challenges facing Pfizer, the outlook for the company's stock is better than many people think. Despite the conventional wisdom that Pfizer's stock will suffer, the company is making significant strides towards achieving its goals. Investors should take note of the recent positive developments and consider investing in this pharmaceutical giant.
NYSE:PFEShort
by FOREXN1
10
Pfizer Analysis 08.02.2022Hello Traders, welcome to this free and educational analysis. I am going to explain where I think this asset is going to go over the next few days and weeks and where I would look for trading opportunities. If you have any questions or suggestions which asset I should analyse tomorrow, please leave a comment below. I will personally reply to every single comment! If you enjoyed this analysis, I would definitely appreciate it, if you smash that like button and maybe consider following my channel. Thank you for watching and I will see you tomorrow!
NYSE:PFE
by basictradingtv
10
PFIZER INC: FUNDAMENTAL ANALYSIS REPORT+NEXT TARGET|MUST READ 🔔Late last month, Pfizer announced that its drug abrocitinib had been approved by Japan's Ministry of Health, Labor and Welfare (MHLW) as a treatment for patients aged 12 and older with moderate to severe atopic dermatitis or eczema. The Japanese approval of abrocitinib under the trade name Cibinqo came just weeks after the UK Medicines and Healthcare Products Regulatory Agency (MHRA) approved the drug for adults and adolescents with moderate to severe eczema. Let's take a look at why the MHLW approved the drug for use in eczema, as well as its sales potential and what it means for Pfizer. Typically, first-line therapy for eczema patients is topical corticosteroids (TCS), which are effective in treating most eczema patients. But for the large minority of eczema patients who do not experience significant benefits from TCS, there is a huge unmet medical need. And this is where Pfizer's Cibinqo can make a big difference in treating complex eczema cases. For context, the leading eczema drug is Dupixent, which was developed jointly by Regeneron and Sanofi. Dupixent is also approved as a complementary treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, bringing the drug's sales to more than $8 billion last year. And although Pfizer will release the full results of the drug's latest phase 3 trial later, Cibinqo was found to outperform Dupixent in all measures of efficacy. More patients who received 200 milligrams of Cibinqo once daily compared to 300 mg of Dupixent once every two weeks reported a four-point improvement in peak itch severity on the numeric rating scale in the second week of treatment compared to baseline levels before treatment. Simply put, the Peak Itch Digital Rating Scale is used by health care providers to measure the intensity of itching in patients with moderate to severe eczema. Although full study data have not yet been published, Cibinqo has demonstrated greater efficacy than Dupixent in reducing itching in patients with eczema in the second week of treatment. This should lead to an improvement in the quality of life of eczema patients. With a better understanding of Cibinqo's effectiveness in treating eczema, we can now explore the sales potential of this drug for Pfizer. Cibinqo's Phase 3 clinical trial showing higher efficacy compared to Dupixent is certainly an advantage. However, in the coming months, when Pfizer presents additional data, it will become clear how much of an efficacy advantage Cibinqo has over Dupixent. This is because last month the U.S. Food and Drug Administration (FDA) issued new warnings for Janus kinase inhibitors such as Cibinqo. This may encourage health care providers worldwide to exercise caution when prescribing Cibinqo in favor of Dupixent if the benefits are deemed to outweigh the risks compared to Dupixent. The encouraging news for Cibinqo is that, at first glance, the percentage of patients who discontinued Cibinqo was similar to those who discontinued Dupixent because of adverse events. There are approximately 105 million adults in Japan, and given that the prevalence of eczema among adults is estimated at 6.5%, there are 6.8 million adults with eczema. Since 23.3% of eczema cases in Japan are estimated to be moderate to severe, there are about 1.6 million adults with moderate to severe eczema. Of these 1.6 million, about 19% will not be able to control their symptoms with TCS alone. Thus, the real market of adult patients in Japan with moderate to severe eczema for Cibinqo is about 300,000. Cibinqo is expected to win 10% or 30,000 of these patients, which conservatively accounts for the remaining efficacy and safety issues of Cibinqo compared to the leader Dupixent. Since the Institute for Economic and Clinical Analysis estimates that the annual price in the United States is between $30,000 and $40,000, and prescriptions in Japan are on average 43% cheaper than in the United States, Cibinqo would have a net price of $10,000 per year. Thus, this eczema indication should generate about $300 million in annual revenue for Pfizer in Japan alone. Although this is a fraction of a percent compared to Pfizer's expected revenue of $78 billion to $80 billion this year, it is a good additional income for the company. Although Cibinqo looks like a promising new drug for Pfizer, the company is not idly waiting for results. While established drugs such as the COVID-19 Comirnaty vaccine and the Prevnar-13 pneumonia vaccine are generating significant revenue, Pfizer is working to discover, research, and commercialize the next line of breakthrough drugs. Pfizer, for example, recently increased its research and development spending from $3.8 billion in the first half of last year to $4.5 billion this year. While no guarantee increased R&D spending will lead to the discovery of more drugs and approvals, it's the best chance pharmaceutical stocks have at innovating and staying relevant. That's why Pfizer's dividend yield of 3.7% is safe for the foreseeable future and is the best choice in its sector for stable income.
NYSE:PFEShort
by FOREXN1
9